Corix Responds to Minority Shareholders Lawsuit
January 10 2018 - 7:15PM
InvestorsHub NewsWire
SURPRISE, AZ -- January 10, 2018 -- InvestorsHub
NewsWire -- Corix Bioscience, Inc., (OTCQB: CXBS) a Wyoming
corporation (“Corix”), acknowledges receipt of the lawsuit filed by
a minority shareholder named George Sharp. Mr. Sharp holds
0.01% of Corix’s issued and outstanding shares of common stock. Mr.
Sharp has filed numerous lawsuits against publicly reporting
companies alleging the same or similar claims.
Corix’s Chief Executive Officer, Michael Ogburn stated, “Corix
denies all allegations of wrongdoing and will respond accordingly
through the judicial process. Notwithstanding his claims that
Corix has diminished value, Mr. Sharp has made settlement proposals
to the company demanding not only financial remuneration, but also
the issuance of additional stock. Corix believes this proposal
contradicts Mr. Sharp’s allegations that the company is not viable
or is being used as a conduit for fraudulent activity.”
Mr. Sharp recently issued a press release dated January 2, 2018
outlining the allegations in his Complaint against Corix.
Corix similarly denies uniformly the allegations in Mr. Sharp’s
press release as inaccurate and untrue. Corix believes Mr.
Sharp’s press release is part of a pattern of abusive litigation
tactics aimed at pressuring Corix to enter into a quick
settlement. In fact, courts have previously barred Mr. Sharp
from issuing inaccurate or defamatory press releases in cases
similar to this. An example can be found here:
http://floridalawsuit.yolasite.com/resources/Injunction%20-%20Executed%209-16-2013.pdf
Corix will provide updates to this press release upon
developments in this litigation.
About Corix Bioscience Inc.
Corix Bioscience, Inc. (“Corix”) is a fully reporting Wyoming
corporation listed as OTCQB:CXBS. Corix is the developer of
proprietary cannabis and industrial hemp strains using tissue cell
cultures to propagate living plants, with plans to patent the
strains to be used in the pharmaceutical medical industries.
Our methods allow us to create and breed new and existing plant
strains from tissue cells free of any pathogens or disease. We grow
these plants to maturity and extract the oils which are the
“medicine” part of the plant. Our sales are focused towards the
medical industry and we are developing brand named products to be
released in early 2018.
Company headquarters are in Phoenix, Arizona and with our
laboratory and processing facility in Carson City, Nevada and we
grow in Genoa, Nevada. We are currently looking at expanding our
footprint into Washington, Oregon, California and Arizona. The
Company’s mission is to create clean and consistent products in
medical grade facilities. Consistency being the key which
will ultima yield a safer and superior product, better for people
and the environment. For more information, please visit Corix’s
website at www.corixbioscience.com
Forward Looking Statement
This press release, and those statements regarding Corix
Bioscience (the “Company”), contain forward-looking statements that
relate to expectations, beliefs, projections, future plans and
strategies, anticipated events and similar expressions.
Forward-looking statements may be identified by use of words such
as "may," "will," "should," "expects," "intends," "plans,"
"anticipates," "believes," "estimates," or "potential" or similar
words or phrases which are predictions of or indicate future events
or trends. Statements such as those concerning potential
acquisition activity, investment objectives, strategies,
opportunities, other plans and objectives for future operations or
economic performance are based on the Company's current
expectations, plans, estimates, assumptions and beliefs that
involve numerous risks and uncertainties. You are cautioned
not to place undue reliance on any forward-looking statements and
the Company disclaims any obligation to publicly update or revise
any forward-looking statement to reflect changes in underlying
assumptions or factors, new information, future events or other
changes. Please refer to Company's filings with the
Securities and Exchange Commission for further
information.
Related Links: http://www.corixbioscience.com
Contact:Christ Froese
623 551 5808
CFroese@CorixBioscience.com
Corix Bioscience (CE) (USOTC:CXBS)
Historical Stock Chart
From Jan 2025 to Feb 2025
Corix Bioscience (CE) (USOTC:CXBS)
Historical Stock Chart
From Feb 2024 to Feb 2025